B7-33
B7-33
About
Specifications
Dosing
A brief reference to the studied B7-33 regimens. Preclinical (mouse) data only; no validated human dosing protocol exists.
Full dosing guideTitration schedule · referenceB7-33
A brief reference to the studied B7-33 regimens. Preclinical (mouse) data only; no validated human dosing protocol exists.
Full dosing guideTitration schedule · referenceAnalytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
B7-33 is a synthetic single-chain peptide derived from the B-chain of human relaxin-2 and the first reported functionally selective (biased) agonist of the RXFP1 receptor. Unlike two-chain native relaxin, it reproduces the core anti-fibrotic signalling (via the pERK1/2 axis) within a single short chain that is far simpler to synthesise.
In preclinical research (the Hossain and Bathgate groups at the Florey Institute), B7-33 showed anti-fibrotic and vasoprotective activity in cell and rodent models of the heart, lung and kidney, reduced infarct size in mice, and — unlike full-length relaxin — did not promote prostate tumour growth.
This is a rare, frontier research compound that Longeva keeps in stock when others will not source it.
No reviews yet
Bought this product? Be the first to tell others — it takes a minute.